Research traces the evolution of a gene variant that reduces the risk of Alzheimer’s disease, finding that it originally evolved in response to infectious bacteria.
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.